Please note that this product was withdrawn from the Union Register of orphan medicinal products in March 2020 on request of the sponsor.
On 28 April 2016, orphan designation (EU/3/16/1649) was granted by the European Commission to Abbvie Ltd, United Kingdom, for humanised recombinant IgG4 anti-human tau antibody (also known as ABBV-8E12) for the treatment of progressive supranuclear palsy.
The sponsorship was transferred to AbbVie Deutschland GmbH & Co. KG, Germany, in May 2018.
This medicine is now known as tilavonemab.
Humanised recombinant IgG4 anti-human tau antibody (tilavonemab)
|Disease / condition||
Treatment of progressive supranuclear palsy
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.